

Accepted Manuscript

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, D. Ross Camidge

PII: S1556-0864(16)31179-0

DOI: [10.1016/j.jtho.2016.10.014](https://doi.org/10.1016/j.jtho.2016.10.014)

Reference: JTHO 381

To appear in: *Journal of Thoracic Oncology*

Received Date: 9 August 2016

Revised Date: 12 October 2016

Accepted Date: 16 October 2016

Please cite this article as: Drilon A, Cappuzzo F, Ignatius Ou S-H, Camidge DR, Targeting MET in Lung Cancer: Will Expectations Finally Be MET?, *Journal of Thoracic Oncology* (2016), doi: 10.1016/j.jtho.2016.10.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title page**Targeting MET in Lung Cancer: Will Expectations Finally Be MET?****Authors**

Alexander Drilon,¹ Federico Cappuzzo,² Sai-Hong Ignatius Ou,³ and D. Ross Camidge⁴

¹Memorial Sloan Kettering Cancer Center, New York, NY; ²AUSL della Romagna, Ravenna, Italy; ³Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; ⁴University of Colorado Cancer Center, Aurora, CO

Corresponding author

Alexander Drilon, MD, Thoracic Oncology Service and Developmental Therapeutics, 300 E 66th St., New York, New York, 10065, Memorial Sloan Kettering Cancer Center, New York, NY; tel: 646-888-4206, fax: 646-888-4263; email: drilona@mskcc.org

Running head

Targeting MET in Lung Cancer

Disclosures

Alexander Drilon: None

Federico Capuzzo: None

Sai Hong Ignatius Ou: Consultant for Pfizer, Roche/Genentech/Chugai, AstraZeneca, Boehringer Ingelheim; Speaker honorarium for Roche/Genentech, AstraZeneca, Boehringer Ingelheim

D. Ross Camidge: Honoraria from Pfizer and Eli Lilly

Target journal

Journal of Thoracic Oncology – review article

Article parameters

Abstract: 198 words

Current word count: 3994 (excluding abstract, acknowledgments, references, figures and tables)

Figures + Tables: 6

References: 71

Download English Version:

<https://daneshyari.com/en/article/5701680>

Download Persian Version:

<https://daneshyari.com/article/5701680>

[Daneshyari.com](https://daneshyari.com)